Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis

Hepatology

Volumn 56, Issue 1, 2012, Pages 300-310

  Lakner, Ashley M ^a,b   Steuerwald, Nury M ^b   Walling, Tracy L ^b   Ghosh, Sriparna ^b   Li, Ting ^b   Mckillop, Iain H ^a,b   Russo, Mark W ^b   Bonkovsky, Herbert L ^b,c,d   Schrum, Laura W ^a,b  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; MICRORNA; MICRORNA 19B; PROCOLLAGEN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FIBROGENESIS; HUMAN; IN VIVO STUDY; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MICRORNAS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84863532308     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25613     Document Type: Article

References (49)

1. Saile B, Ramadori G. Inflammation, damage repair and liver fibrosis-role of cytokines and different cell types. Z Gastroenterol 2007; 45: 77-86.
2. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172.
3. Neubauer K, Knittel T, Aurisch S, Fellmer P, Ramadori G. Glial fibrillary acidic protein-a cell type specific marker for Ito cells in vivo and in vitro. J Hepatol 1996; 24: 719-730.
4. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, ten Dijke P, et al. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGF-beta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett 2001; 502: 4-10.
5. Kanzler S, Meyer E, Lohse AW, Schirmacher P, Henninger J, Galle PR, Blessing M. Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 2001; 20: 5015-5024.
6. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. HEPATOLOGY 2000; 32: 247-255.
7. Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N, Takeshita A, et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 2000; 11: 33-42.
8. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. HEPATOLOGY 2000; 31: 1094-1106.
9. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96: 12719-12724.
10. Lakner AM, Moore CC, Gulledge AA, Schrum LW. Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation. World J Gastroenterol 2010; 16: 5047-5056.
11. Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: fad or future of liver disease. World J Gastroenterol 2011; 17: 2536-2542.
12. Guo CJ, Pan Q, Jiang B, Chen GY, Li DG. Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 2009; 14: 1331-1340.
13. Guo CJ, Pan Q, Li DG, Sun H, Liu BW. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol 2009; 50: 766-778.
14. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009; 583: 759-766.
15. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 2010; 298: G101-106.
16. Ogawa T, Iizuka M, Sekiya Y, Yoshizato K, Ikeda K, Kawada N. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun 2010; 391: 316-321.
17. Lakner AM, Walling TL, McKillop IH, Schrum LW. Altered aquaporin expression and role in apoptosis during hepatic stellate cell activation. Liver Int 2011; 31: 42-51.
18. Schrum LW, Black D, Iimuro Y, Rippe RA, Brenner DA, Behrns KE. c-Jun does not mediate hepatocyte apoptosis following NFkappaB inhibition and partial hepatectomy. J Surg Res 2000; 88: 142-149.
19. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006; 106: 1677-1684.
20. Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock 2008; 30: 197-205.
21. Kitamura Y, Ninomiya H. Smad expression of hepatic stellate cells in liver cirrhosis in vivo and hepatic stellate cell line in vitro. Pathol Int 2003; 53: 18-26.
22. Bauge C, Cauvard O, Leclercq S, Galera P, Boumediene K. Modulation of transforming growth factor beta signalling pathway genes by transforming growth factor beta in human osteoarthritic chondrocytes: involvement of Sp1 in both early and late response cells to transforming growth factor beta. Arthritis Res Ther 2011; 13: R23.
23. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-1022.
24. Miyazono K. Positive and negative regulation of TGF-beta signaling. J Cell Sci 2000; 113( Pt 7): 1101-1109.
25. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-2092.
26. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56: 1830-1838.
27. Isono M, Soda M, Inoue A, Akiyoshi H, Sato K. Reverse transformation of hepatic myofibroblast-like cells by TGF-beta1/LAP. Biochem Biophys Res Commun 2003; 311: 959-965.
28. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 361-368.
29. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22( Suppl 1): S79-84.
30. Chen XM. MicroRNA signatures in liver diseases. World J Gastroenterol 2009; 15: 1665-1672.
31. Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009; 33: 1704-1710.
32. Jin X, Ye YF, Chen SH, Yu CH, Liu J, Li YM. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis 2009; 41: 289-297.
33. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. HEPATOLOGY 2011; 53: 209-218.
34. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010; 40: 762-773.
35. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, et al. The myc-miR-17≈92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 2010; 70: 8233-8246.
36. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10:769-779.
37. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009; 175: 3-16.
38. Davis BN, Hata A. Regulation of microRNA biogenesis: a miRiad of mechanisms. Cell Commun Signal 2009; 7: 18.
39. Zhou R, Hu G, Gong AY, Chen XM. Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res 2010; 38: 3222-3232.
40. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454: 56-61.
41. Yang X, Haurigot V, Zhou S, Luo G, Couto LB. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster. HEPATOLOGY 2010; 52: 1877-1887.
42. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017.
43. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011; 120: 183-193.
44. De Martin E, Senzolo M, Gambato M, Germani G, Vitale A, Russo FR, et al. Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review. Transplant Proc 2010; 42: 2223-2225.
45. Szabo G, Katz E, Bonkovsky HL. Management of recurrent hepatitis C after liver transplantation: a concise review. Am J Gastroenterol 2000; 95: 2164-2170.
46. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-18.
47. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14.
48. Russo MW, Firpi RJ, Nelson DR, Schoonhoven R, Shrestha R, Fried MW. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 2005; 11: 1235-1241.
49. Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, Shimotohno K. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Medical Genomics 2010; 3: 48.